Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques

被引:48
|
作者
Martínez-Ramírez, A [1 ]
Rodríguez-Perales, S [1 ]
Meléndez, B [1 ]
Martínez-Delgado, B [1 ]
Urioste, M [1 ]
Cigudosa, JC [1 ]
Benítez, J [1 ]
机构
[1] Inst Salud Carlos III, Spanish Natl Canc Ctr, CNIO,Mol Pathol Program, Dept Human Genet, Madrid, Spain
关键词
D O I
10.1016/S0165-4608(02)00670-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The A673 cell line was established from a patient with a primary rhabdomyosarcoma (RMS), which is referred to in the literature either as a Ewing tumor (ET) or as RMS. Although the two tumoral types are associated with specific and well-characterized translocations, no cytogenetic report on this cell line has been published. We characterized the A673 cell line using a combination of spectral karyotyping (SKY), fluorescence in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR), which revealed the presence of a complex karyotype and a translocation involving chromosomes 11 and 22 and the fusion of EWS and FL11 genes, both events being specific to ET. Neither cytogenetics nor molecular alterations specific to RMS were found. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:138 / 142
页数:5
相关论文
共 50 条
  • [1] Re: Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques
    Coleman, N
    Roberts, I
    CANCER GENETICS AND CYTOGENETICS, 2004, 148 (01) : 86 - 86
  • [2] Inhibition of AKT-signalling sensitizes A673 Ewing sarcoma cell line to doxorubicin
    Galembikova, A.
    Boichuk, S. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S1364 - S1365
  • [3] SIRT5 Is Required for Viability of the Ewing Sarcoma Cell Line A673 and the Osteosarcoma Cell Line U2OS
    Seward, David
    Bergholtz, Sarah
    Pederson, Elizabeth
    Skinner, Mary
    Park, Jeongsoon
    Lawlor, Elizabeth R.
    Lombard, David
    MODERN PATHOLOGY, 2016, 29 : 25A - 26A
  • [4] SIRT5 Is Required for Viability of the Ewing Sarcoma Cell Line A673 and the Osteosarcoma Cell Line U2OS
    Seward, David
    Bergholtz, Sarah
    Pederson, Elizabeth
    Skinner, Mary
    Park, Jeongsoon
    Lawlor, Elizabeth R.
    Lombard, David
    LABORATORY INVESTIGATION, 2016, 96 : 25A - 26A
  • [5] Targeting of AKT-Signaling Pathway Potentiates the Anti-cancer Efficacy of Doxorubicin in A673 Ewing Sarcoma Cell Line
    A. Galembikova
    S. Boichuk
    BioNanoScience, 2021, 11 : 1070 - 1082
  • [6] Targeting of AKT-Signaling Pathway Potentiates the Anti-cancer Efficacy of Doxorubicin in A673 Ewing Sarcoma Cell Line
    Galembikova, A.
    Boichuk, S.
    BIONANOSCIENCE, 2021, 11 (04) : 1070 - 1082
  • [7] PHYSICAL AND BIOLOGICAL CHARACTERIZATION OF A GROWTH-INHIBITORY ACTIVITY PURIFIED FROM THE NEUROEPITHELIOMA CELL-LINE A673
    STAM, K
    STEWART, AA
    QU, GY
    IWATA, KK
    FENYO, D
    CHAIT, BT
    MARSHAK, DR
    HALEY, JD
    BIOCHEMICAL JOURNAL, 1995, 305 : 87 - 92
  • [8] CHARACTERIZATION OF HIGH-MOLECULAR-WEIGHT TRANSFORMING GROWTH-FACTORS (HMW TGFS) IN CONDITIONED MEDIUM OF HUMAN RHABDOMYOSARCOMA CELL-LINE A673
    STROMBERG, K
    HUDGINS, WR
    FRYLING, CM
    DEDMAN, JR
    PARDUE, RL
    HARGREAVES, WR
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 44 - 44
  • [9] Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line
    Barenboim-Stapleton, L
    Yang, XZ
    Tsokos, M
    Wigginton, JM
    Padilla-Nash, H
    Ried, T
    Thiele, CJ
    CANCER GENETICS AND CYTOGENETICS, 2005, 157 (02) : 109 - 117
  • [10] Molecular cytogenetic characterization of a cell clone from a rat fibrosarcoma cell line
    Louzada, S.
    Adega, F.
    Chaves, R.
    CHROMOSOME RESEARCH, 2010, 18 (06) : 718 - 718